SG11202110584TA - Monitoring gene therapy - Google Patents
Monitoring gene therapyInfo
- Publication number
- SG11202110584TA SG11202110584TA SG11202110584TA SG11202110584TA SG11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA SG 11202110584T A SG11202110584T A SG 11202110584TA
- Authority
- SG
- Singapore
- Prior art keywords
- gene therapy
- monitoring gene
- monitoring
- therapy
- gene
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962833875P | 2019-04-15 | 2019-04-15 | |
PCT/US2020/028102 WO2020214582A1 (en) | 2019-04-15 | 2020-04-14 | Monitoring gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202110584TA true SG11202110584TA (en) | 2021-10-28 |
Family
ID=72837570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202110584TA SG11202110584TA (en) | 2019-04-15 | 2020-04-14 | Monitoring gene therapy |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220308070A1 (en) |
EP (1) | EP3955972A4 (en) |
JP (2) | JP2022529433A (en) |
KR (1) | KR20220021906A (en) |
CN (1) | CN114072181A (en) |
AU (1) | AU2020258371A1 (en) |
BR (1) | BR112021020499A2 (en) |
CA (1) | CA3135666A1 (en) |
IL (1) | IL287186A (en) |
MA (1) | MA55727A (en) |
MX (1) | MX2021012541A (en) |
SG (1) | SG11202110584TA (en) |
WO (1) | WO2020214582A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023230098A1 (en) | 2022-05-23 | 2023-11-30 | Logicbio Therapeutics, Inc. | Gene therapy compositions and methods of use thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632800B1 (en) * | 1999-08-17 | 2003-10-14 | Mayo Foundation For Medical Education And Research | System for monitoring the expression of transgenes |
CA2526120A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
US20090247475A1 (en) * | 2004-03-05 | 2009-10-01 | The Regents Of The University Of California | Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies |
KR20220100728A (en) * | 2014-03-21 | 2022-07-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Genome editing without nucleases |
WO2020032986A1 (en) * | 2018-08-10 | 2020-02-13 | Logicbio Therapeutics, Inc. | Non-disruptive gene therapy for the treatment of mma |
-
2020
- 2020-04-14 SG SG11202110584TA patent/SG11202110584TA/en unknown
- 2020-04-14 JP JP2021560957A patent/JP2022529433A/en active Pending
- 2020-04-14 WO PCT/US2020/028102 patent/WO2020214582A1/en active Application Filing
- 2020-04-14 MA MA055727A patent/MA55727A/en unknown
- 2020-04-14 EP EP20790517.5A patent/EP3955972A4/en active Pending
- 2020-04-14 AU AU2020258371A patent/AU2020258371A1/en active Pending
- 2020-04-14 KR KR1020217037025A patent/KR20220021906A/en unknown
- 2020-04-14 CN CN202080029191.8A patent/CN114072181A/en active Pending
- 2020-04-14 CA CA3135666A patent/CA3135666A1/en active Pending
- 2020-04-14 MX MX2021012541A patent/MX2021012541A/en unknown
- 2020-04-14 BR BR112021020499A patent/BR112021020499A2/en unknown
- 2020-04-14 US US17/603,935 patent/US20220308070A1/en active Pending
-
2021
- 2021-10-11 IL IL287186A patent/IL287186A/en unknown
-
2024
- 2024-06-10 JP JP2024093669A patent/JP2024107256A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3955972A4 (en) | 2023-01-11 |
EP3955972A1 (en) | 2022-02-23 |
KR20220021906A (en) | 2022-02-22 |
US20220308070A1 (en) | 2022-09-29 |
JP2024107256A (en) | 2024-08-08 |
CA3135666A1 (en) | 2020-10-22 |
CN114072181A (en) | 2022-02-18 |
MA55727A (en) | 2022-02-23 |
BR112021020499A2 (en) | 2021-12-07 |
AU2020258371A1 (en) | 2021-10-28 |
MX2021012541A (en) | 2021-11-12 |
JP2022529433A (en) | 2022-06-22 |
IL287186A (en) | 2021-12-01 |
WO2020214582A1 (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA195571S (en) | Stimulator | |
IL279685A (en) | Gene therapy | |
GB201900702D0 (en) | Therapy | |
SI3612237T1 (en) | Gene therapy | |
GB201905301D0 (en) | Gene therapy | |
IL280165A (en) | Glucocerebrosidase gene therapy | |
ZA202100244B (en) | Combinatorial gene therapy | |
GB201707212D0 (en) | Gene therapy for ciliopathies | |
GB201912191D0 (en) | New therapy | |
IL287186A (en) | Monitoring gene therapy | |
GB201817470D0 (en) | Gene therapy | |
GB201802326D0 (en) | Gene therapy | |
GB201701968D0 (en) | Gene therapy | |
GB201918752D0 (en) | New therapy | |
EP3760209C0 (en) | Ischemic-lesion-site-specific gene therapy | |
GB201906864D0 (en) | Combination therapy | |
GB201818579D0 (en) | New therapy | |
GB201814036D0 (en) | New therapy | |
GB201820982D0 (en) | Gene Therapy | |
GB201811541D0 (en) | Gene therapy | |
IL277696A (en) | Gene therapy for oxidative stress | |
GB201801511D0 (en) | Gene therapy | |
GB201919036D0 (en) | Therapy | |
GB201916983D0 (en) | Therapy | |
GB201914848D0 (en) | Therapy |